Natixis Advisors, L.P. Exelixis, Inc. Transaction History
Natixis Advisors, L.P.
- $54.1 Billion
- Q1 2025
A detailed history of Natixis Advisors, L.P. transactions in Exelixis, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 69,922 shares of EXEL stock, worth $2.96 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69,922
Previous 60,850
14.91%
Holding current value
$2.96 Million
Previous $2.03 Million
27.44%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding EXEL
# of Institutions
613Shares Held
257MCall Options Held
1.57MPut Options Held
730K-
Black Rock Inc. New York, NY33.5MShares$1.42 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA28.7MShares$1.21 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA22.5MShares$955 Million4.78% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.8MShares$628 Million0.88% of portfolio
-
State Street Corp Boston, MA11.8MShares$500 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $13.6B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...